Gubra will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14-16.
Markus Rohrwild, CEO of Gubra, will participate in a fireside chat on Wednesday, September 16, at 1:50 p.m. EDT (7:50 p.m. CEST).
A live audio webcast of the fireside chat will be available at:
https://event.webcasts.com/starthere.jsp?ei=1773928&tp_key=e3b909d63e&tp_special=8. A replay of the webcast will be available at https://www.gubra.dk/investors.
Contacts at Gubra
Media: Marianne Thomas ([email protected], +45 2483 2663)
Investors: Kristian Borbos ([email protected], +45 3080 8035) and Adam Lange ([email protected], +45 6646 1589)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025.
See www.gubra.dk for more information.
